Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IDYA Stock Forecast 2026-2027
$28.32
Current Price
$2.49B
Market Cap
Buy 16
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to IDYA Price Targets
+186.0%
To High Target of $81.00
+80.1%
To Median Target of $51.00
+23.6%
To Low Target of $35.00
IDYA Price Momentum
+0.5%
1 Week Change
-8.6%
1 Month Change
+62.6%
1 Year Change
-18.1%
Year-to-Date Change
-27.9%
From 52W High of $39.28
+68.2%
From 52W Low of $16.84
📊 TOP ANALYST CALLS
Did IDYA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ideaya is one of their latest high-conviction picks.
Latest IDYA Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, IDYA has a bullish consensus with a median price target of $51.00 (ranging from $35.00 to $81.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $28.32, the median forecast implies a 80.1% upside. This outlook is supported by 16 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Corinne Jenkins at Goldman Sachs, suggesting a 23.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IDYA Analyst Ratings
16
Buy
2
Hold
0
Sell
IDYA Price Target Range
Low
$35.00
Average
$51.00
High
$81.00
Current: $28.32
Latest IDYA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IDYA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2026 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $50.00 |
| Apr 14, 2026 | Wedbush | Robert Driscoll | Outperform | Maintains | $58.00 |
| Apr 14, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $53.00 |
| Apr 14, 2026 | Guggenheim | Paul Jeng | Buy | Maintains | $54.00 |
| Apr 14, 2026 | Wells Fargo | Eva Fortea Verdejo | Overweight | Maintains | $48.00 |
| Apr 14, 2026 | Goldman Sachs | Corinne Jenkins | Neutral | Maintains | $35.00 |
| Mar 31, 2026 | Wedbush | Robert Driscoll | Outperform | Reiterates | $52.00 |
| Feb 19, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $65.00 |
| Feb 18, 2026 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $49.00 |
| Feb 18, 2026 | Wedbush | Robert Driscoll | Outperform | Maintains | $52.00 |
| Feb 18, 2026 | Guggenheim | Paul Jeng | Buy | Reiterates | $50.00 |
| Jan 21, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $45.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $50.00 |
| Jan 6, 2026 | Truist Securities | Gregory Renza | Buy | Maintains | $60.00 |
| Nov 24, 2025 | Truist Securities | Gregory Renza | Buy | Initiates | $59.00 |
| Nov 11, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $46.00 |
| Oct 23, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $79.00 |
| Oct 21, 2025 | Goldman Sachs | Corinne Jenkins | Neutral | Maintains | $30.00 |
| Oct 21, 2025 | BTIG | Justin Zelin | Buy | Reiterates | $62.00 |
| Oct 21, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $41.00 |
Ideaya Biosciences Inc (IDYA) Competitors
The following stocks are similar to Ideaya based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ideaya Biosciences Inc (IDYA) Financial Data
Valuation Metrics
Market Cap
$2.49B
Enterprise Value
$1.85B
P/E Ratio
N/A
PEG Ratio
-8.5x
Price/Sales
11.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-1,654.6%
Net Margin
-62.2%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+27.0%
Current Ratio
10.7x
Debt/Equity
3.1x
ROE
-14.3%
ROA
-10.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ideaya Biosciences Inc (IDYA) Business Model
About Ideaya Biosciences Inc
What They Do
Develops targeted therapeutics for oncology.
Business Model
The company operates by discovering and developing precision medicine therapies aimed at specific patient populations identified through molecular diagnostics. It generates revenue primarily through the advancement of its clinical pipeline, which includes various drugs currently in different phases of clinical trials, as well as through strategic partnerships with larger pharmaceutical companies.
Additional Information
Ideaya Biosciences has a robust pipeline featuring several drug candidates targeting specific mutations and conditions, with strategic alliances with major industry players like GlaxoSmithKline and Pfizer. Incorporated in 2015 and based in South San Francisco, the company is positioned at the forefront of precision oncology, leveraging innovative research platforms to enhance drug discovery.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
131
CEO
Mr. Yujiro S. Hata
Country
United States
IPO Year
N/A
Website
www.ideayabio.comIdeaya Biosciences Inc (IDYA) Latest News & Analysis
Latest News
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
4 days ago
Quick Summary
IDEAYA Biosciences' darovasertib trial met its primary endpoint, with full data due at ASCO. NDA filing is targeted for H2 2026. The company has ~$973M in cash, guiding runway into 2030.
Why It Matters
The successful trial of darovasertib boosts IDEAYA's prospects, potentially increasing stock value. Upcoming trials and strong cash reserves indicate robust growth and sustainability.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IDEAYA Biosciences reported a quarterly loss of $1.11 per share, exceeding the Zacks Consensus Estimate of $1.07, and worsening from a loss of $0.82 per share a year earlier.
Why It Matters
IDEAYA's larger-than-expected quarterly loss could indicate worsening financial health, potentially impacting stock performance and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
IDEAYA Biosciences announced that its darovasertib combination trial met primary endpoints. The FDA will review its NDA for treating metastatic uveal melanoma, with submission starting in May 2026.
Why It Matters
Successful trial results and FDA review for IDEAYA's darovasertib could lead to market approval, boosting stock value and investor confidence in the company's growth potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IDEAYA Biosciences granted non-qualified stock options for 237,800 shares to five new employees as part of its compensation strategy, effective April 30, 2026.
Why It Matters
The stock options granted to new employees signal growth and investment in talent, potentially enhancing IDEAYA's innovation and future profitability, influencing investor sentiment positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
IDEAYA Biosciences (Nasdaq: IDYA) will present complete data from the Phase 2/3 trial of darovasertib and crizotinib for metastatic uveal melanoma at the ASCO Annual Meeting on May 29-June 2, 2026.
Why It Matters
IDEAYA's late-breaking presentation at ASCO highlights significant clinical trial results for darovasertib, potentially impacting stock value and investor sentiment in oncology markets.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Ideaya Biosciences stock neared a breakout after reporting positive test results for its experimental melanoma treatment.
Why It Matters
Positive test results for Ideaya's melanoma treatment can lead to increased investor confidence, potential stock price surge, and interest in future drug development prospects.
Source: Investors Business Daily
Market Sentiment:
Positive
Frequently Asked Questions About IDYA Stock
What is Ideaya Biosciences Inc's (IDYA) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, Ideaya Biosciences Inc (IDYA) has a median price target of $51.00. The highest price target is $81.00 and the lowest is $35.00.
Is IDYA stock a good investment in 2026?
According to current analyst ratings, IDYA has 16 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $28.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IDYA stock?
Wall Street analysts predict IDYA stock could reach $51.00 in the next 12 months. This represents a 80.1% increase from the current price of $28.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ideaya Biosciences Inc's business model?
The company operates by discovering and developing precision medicine therapies aimed at specific patient populations identified through molecular diagnostics. It generates revenue primarily through the advancement of its clinical pipeline, which includes various drugs currently in different phases of clinical trials, as well as through strategic partnerships with larger pharmaceutical companies.
What is the highest forecasted price for IDYA Ideaya Biosciences Inc?
The highest price target for IDYA is $81.00 from at , which represents a 186.0% increase from the current price of $28.32.
What is the lowest forecasted price for IDYA Ideaya Biosciences Inc?
The lowest price target for IDYA is $35.00 from Corinne Jenkins at Goldman Sachs, which represents a 23.6% increase from the current price of $28.32.
What is the overall IDYA consensus from analysts for Ideaya Biosciences Inc?
The overall analyst consensus for IDYA is bullish. Out of 27 Wall Street analysts, 16 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $51.00.
How accurate are IDYA stock price projections?
Stock price projections, including those for Ideaya Biosciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 8:37 AM UTC